Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen

M. Freue, M. Kjaer, C. Boni, J. Joliver, F. Jänicke, H. B. Willemse, R. C. Coombes, S. Van Belle, R. Pérez-Carrión, J. Zieschang, P. Ibarra De Palacios, C. Rose

Research output: Contribution to journalArticle

Abstract

The aim of the trial was to compare efficacy and safety of the aromatase inhibitor formestane (250 mg i.m. given every 2 weeks) with the progestin megestrol acetate (160 mg administered orally once daily), as second-line therapy in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. A total of 547 patients were enrolled. Analyses revealed no statistically significant or clinically relevant difference between treatments with respect to time endpoints. In the intent-to-treat analysis, the median values for time to failure and overall survival for formestane were 169 and 561 days, respectively. The corresponding values for megestrol acetate were 169 days and 597 days, respectively. Overall response rates were comparable for formestane and megestrol acetate (16.3% vs 20.3%). Formestane was better tolerated than megestrol acetate. In the megestrol acetate group, cardiovascular events, weight increase, and vaginal haemorrhage were significantly more frequent than in the formestane group. Thus, formestane is a suitable alternative to progestins in patients previously treated with tamoxifen. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalBreast
Volume9
Issue number1
DOIs
Publication statusPublished - Feb 2000

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen'. Together they form a unique fingerprint.

  • Cite this

    Freue, M., Kjaer, M., Boni, C., Joliver, J., Jänicke, F., Willemse, H. B., Coombes, R. C., Van Belle, S., Pérez-Carrión, R., Zieschang, J., Ibarra De Palacios, P., & Rose, C. (2000). Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast, 9(1), 9-16. https://doi.org/10.1054/brst.1999.0118